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Abstract
Background: Little is known about the prevalence and correlates of intimate partner violence (IPV) among gay,
bisexual and other men who have sex with men (GBMSM) in the UK. The aim of this study was to investigate the
prevalence of IPV, associations of socio-economic and psychosocial factors with IPV, and the association of IPV with
depression and sexual behaviour, among GBMSM in the PROUD trial of pre-exposure prophylaxis (PrEP).
Methods: PROUD enrolled 544 HIV-negative participants in England from 2012 to 2014; participants were randomised
to immediate or deferred PrEP. This analysis included 436 GBMSM who had IPV data at month-12 and/or 24. Prevalence
of IPV victimization and perpetration (lifetime, and in the past year) was assessed at these time-points. Generalized
estimating equations were used to investigate associations with IPV, using pooled data from both time-points.
Results: At month-12 (N = 410), 44.9% of men reported ever being a victim of IPV, 15.6% in the last year, and 19.5%
reported ever perpetrating IPV, 7.8% in the last year. At month-24 (N = 333), the corresponding prevalence was 40.2 and
14.7% for lifetime and past year IPV victimization and 18.0 and 6.9% for lifetime and past year IPV perpetration. IPV
prevalence did not differ by randomised arm. Men reporting internalized homophobia and sexualized drug use were
more likely to report IPV. Lifetime and last year experience of IPV victimization and perpetration were strongly associated
with depressive symptoms (PHQ-9≥ 10) (adjusted for socio-demographics: lifetime IPV victimization PR 2.57 [95% CI:
1.71, 3.86]; past year IPV victimization PR 2.93 [95% CI: 1.96, 4.40]; lifetime IPV perpetration PR 2.87 [95% CI: 1.91, 4.32];
past year IPV perpetration PR 3.47 [95% CI: 2.13, 5.64], p < 0.001 for all); IPV was not consistently associated with measures
of condomless anal sex or high partner numbers.
Conclusions: GBMSM at high-risk of HIV who are seeking/taking PrEP may experience a high burden of IPV, which may
be linked to depression. Training on awareness of and enquiry for IPV among GBMSM in sexual health clinics is
recommended.
Trial registration: ClinicalTrials.gov identifier: NCT02065986. Registered 19 February 2014 (retrospectively registered).
Keywords: Men who have sex with men (MSM), Intimate partner violence (IPV), Depression, Sexual risk behaviour, HIV,
STI, Pre-exposure prophylaxis (PrEP)
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Background
Intimate partner violence (IPV) is defined as physical,
sexual, or psychological harm by a current or former
partner or spouse [1]. IPV may be experienced as a vic-
tim or perpetrator, or as both, often referred to as bidir-
ectional/reciprocal IPV [2]. There is a growing body of
research on the prevalence of IPV victimization among
gay, bisexual and other men who have sex with men
(GBMSM) in the U.S. [3–5], although data on IPV per-
petration are limited.
Few studies have investigated IPV among GBMSM in
the UK [6–8]. In a study of GBMSM attending a genito-
urinary medicine (GUM) clinic in London in 2010–11
(N = 519) [7], the prevalence of lifetime IPV
victimization was 34% and lifetime IPV perpetration was
16%, which appears high in relation to general UK popu-
lation estimates [9, 10].
Evidence from a recent meta-analysis of mainly U.S.
studies suggests that experiences of IPV are associated
with depression, drug use, sexual risk behaviour, and HIV
seropositivity among GBMSM [3]. It has been suggested
in syndemic theory that it is the synergistic interaction of
two or more co-occurring psychosocial factors, such as
childhood sexual abuse, IPV, depression, and drug use that
may compound the risk of HIV/STIs [11, 12].
The arena of HIV prevention has changed dramatically
with the introduction of pre-exposure prophylaxis (PrEP)
medication to prevent HIV infection [13–15]. Although
PrEP is not currently freely available on the UK National
Health Service, an increasing number of GBMSM are
using PrEP in the UK. The PROUD clinical trial evaluated
the efficacy of PrEP against HIV acquisition among
GBMSM in England [15, 16]. One concern of the trial was
that PrEP use could potentially negatively impact upon
vulnerability towards pressure from a partner to have sex
without a condom. Therefore, the PROUD trial included
inquiry on sexual, psychological, and physical IPV on the
annual questionnaires, and whether participation in the
trial had influenced experiences of IPV.
This analysis uses data from the 12- and 24-month
follow-up of the PROUD trial. The aim is to investigate
among HIV-negative GBMSM at high-risk for acquiring
HIV infection, and in the context of PrEP use: (i) preva-
lence of IPV victimization and perpetration, and the im-
pact of participating in a PrEP trial on experiences of
IPV; (ii) associations of socio-economic status and psy-
chosocial factors with IPV; (iii) association of IPV with
depressive symptoms; (iv) relationships of IPV and de-
pression with sexual behaviours.
Methods
The PROUD trial was a multi-centre, pragmatic open
label randomised clinical trial evaluating the benefit of
PrEP as part of a package of HIV risk reduction
interventions for HIV-negative GBMSM and trans
women. Only three trans women enrolled in PROUD,
and therefore data cannot be presented separately for
trans women. The study was reviewed and approved by
London Bridge Research Ethics Committee. Participants
were enrolled at 13 GUM clinics in England between
November 2012 and April 2014. Volunteers were eligible
if they met the following criteria: male at birth, aged 18
years or over, tested HIV-negative on the day of enrol-
ment or in the past four weeks, and reported condom-
less anal sex (CAS) with a man in the past three months
and expected to have CAS again in the next three
months [15]. Volunteers were randomized 1:1 to an im-
mediate start of daily oral PrEP or a deferred start after
12 months of follow-up. However, during follow-up, an
unexpectedly high incidence of HIV was observed in the
deferral arm (9.0 per 100 person-years, 90% CI: 6.1,
12.8), which led to the decision by the trial steering
committee in October 2014 to offer all participants
PrEP. Participants had the opportunity to remain in
follow-up for at least two years. Participants were asked
to self-complete a paper questionnaire at baseline and
an extended questionnaire, excluding socio-demographic
data, on an approximately annual basis thereafter.
IPV
Questions on IPV were not included in the baseline
questionnaire but were included in the annual question-
naires, given concern over the possible impact of PrEP
use on vulnerability towards pressure from partners to
have sex without a condom. The IPV questions were
based on the ‘Health and Relationships survey’ devised
as part of a previous study in London [7]. Ten questions
about psychological, physical, and sexual IPV were in-
corporated into the PROUD 12 and 24-month question-
naires. Five asked about victimization and five about
perpetration; in each case response options differentiated
experiences of lifetime IPV or IPV in the last year, and
IPV with a current or former partner in the last year
(Figs. 1 and 2 and question 19 in Additional file 1). A
positive response to any one of the five respective ques-
tions was considered to indicate lifetime IPV
victimization or lifetime IPV perpetration. Reporting any
IPV victimization but no IPV perpetration was consid-
ered to indicate unidirectional IPV victimization. Like-
wise, the reverse was considered to indicate
unidirectional IPV perpetration. A missing response was
considered to indicate no IPV. In order to evaluate the
impact of participating in the PROUD trial on IPV (in-
cluding sexual violence), participants were asked the fol-
lowing question after enquiry about IPV; ‘If you
answered yes in the last year to any question above, do
you think joining PROUD has influenced these
behaviours?’
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Clinically significant depressive symptoms
The Patient Health Questionnaire (PHQ-9) was used to
measure the prevalence of depressive symptoms at
month-12 and 24 (see question 16 in Additional file 1)
[17]. In this analysis, a cut-off point of 10 or greater (out
of a possible 27) for the total PHQ-9 score across the
nine questions was used to indicate depressive symp-
toms. The PHQ-9 has been found to have good validity
in a number of studies [17–28].
Sexual behaviour measures
Seven measures of sexual behaviour in the past three
months were derived at month-12 and 24; five mea-
sures of CAS and two measures of partner numbers.
(i) CAS with at least two receptive or at least two
insertive partners, (ii) CAS with at least five receptive
or at least five insertive partners, (iii) CAS with an
HIV-positive partner not known to be on antiretro-
viral treatment, (iv) receptive CAS with an
HIV-positive partner not known to be on antiretro-
viral treatment, (v) most recent CAS with an un-
known/HIV-positive partner not known to be on
antiretroviral treatment, (vi) ten or more new anal
sex partners, and (vii) receptive anal sex with ten or
more partners. In measures (i) and (ii), numbers of
insertive and receptive partners reported were consid-
ered separately as participants may have referred to
the same partner for both insertive and receptive
CAS. For instance, participants were not classified as
positive for CAS with ≥2 partners if they reported
one receptive and one insertive CAS partner (n = 37
at month-12 and n = 29 at month-24). In measures
(vi) and (vii), a cut-off of ten or more partners was
chosen given the very high prevalence of reporting
five or more partners: 44.6% for new anal sex part-
ners and 51.5% for receptive anal sex partners. A
missing response was considered to indicate that the
sexual behaviour did not occur.
Use of drugs in a sexual context
At month-12 and 24, participants were asked whether,
in the past three months, they had engaged in sex after
recreational drug use, referred to as sexualized drug use.
A missing response was considered to indicate no sexu-
alized drug use. Sexualized use of drugs may be a proxy
measure for chemsex, which is the use of specific
Fig. 1 Prevalence of IPV victimization and perpetration at month-12 (N = 410)
Miltz et al. BMC Public Health          (2019) 19:431 Page 3 of 17
psychoactive substances (usually one or more of mephe-
drone, gamma-hydroxybutrate/gamma-butyrolactone [GHB/
GBL] and methamphetamine) during/immediately before
sex to stimulate sexual arousal [29].
Age at first anal sex
Data on age at anal sex debut with a male were collected
at month-12 and 24. The UK Sexual Offences Act 2003
stipulates the legal age of sexual consent to be 16 and that
children under age 13 have no legal capacity to consent to
any form of sexual activity since they cannot fully compre-
hend nor are they developmentally prepared for it [30].
Two measures of age at anal sex debut were investigated,
including cut-offs of age < 13 and age ≤ 15. Reports of sex-
ual intercourse before age 13 may include experiences of
childhood sexual abuse (CSA), however, since information
was not collected on the age of the sexual partner and
whether they felt forced, it is possible that some partici-
pants may not have experienced forced/coerced sex. Fur-
thermore, experiences of CSA may occur at ages older
than 13 years. Therefore, although it was of interest in this
analysis to investigate a very young age at sexual debut as
this measure may include many cases of CSA, it may not
reflect or pick up all sexual abuse experienced.
Internalized homophobia
The concept of internalized homophobia is described in
Meyer’s minority stress theory as a consequence of per-
petual negative feedback and shaming in the form of
homophobic stereotyping and prejudice [31]. Eight ques-
tions about attitudes towards gay sexuality were asked at
month-12 and 24 (see question 22 in Additional file 1)
based on the 26-item Internalized Homophobia Scale
(IHS) [32]. Reporting one or more negative attitudes to-
wards gay sexuality (agree/disagree depending on the
phrasing of the question) was considered to be indicative
of internalized homophobia. A missing response was
considered to indicate no internalized homophobia.
Statistical analysis
The analysis is based on PROUD participants who com-
pleted either the 12- or 24-month questionnaire. Results
Fig. 2 Prevalence of IPV victimization and perpetration at month-24 (N = 333)
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are presented in the tables for lifetime and last year experi-
ences of IPV victimization (yes or no/missing) and lifetime
and last year experiences of IPV perpetration (yes or no/
missing). Experiences of IPV victimization and perpetra-
tion were also categorized into a single variable as follows:
neither victimization nor perpetration, unidirectional IPV
victimization; unidirectional IPV perpetration; both
victimization and perpetration. Prevalence and 95% confi-
dence interval (CI) of the IPV measures were assessed.
The main analysis of factors associated with IPV was based
on pooled data from the 12- and 24-month time-points (as
IPV and psychosocial factors were collected at both
time-points) and used generalized estimating equations
(GEE). Individuals who contributed data at both time-
points were included in the GEE model twice; the use of
robust standard errors account for non-independence of
responses. GEEs were fitted using Poisson models with a
log link in order to produce prevalence ratios (PRs) and
compound symmetry for the correlational structure [33,
34]. For socio-demographic factors that were only col-
lected at baseline, baseline values were used throughout,
with the exception of age, for which age at the specific
questionnaire completion was used. Associations of
socio-demographic and psychosocial factors with IPV mea-
sures are presented unadjusted and adjusted for key
socio-demographic factors assumed not to be on the causal
pathway. These were: age [< 25, 25–29, 30–39, 40+ years],
country of birth [UK born or non-UK born/missing], uni-
versity education [yes or no/missing]), sexual identity [gay
or bisexual/straight], and study region [London or outside
London]. Associations of IPV measures with depressive
symptoms, and with sexual behaviours were assessed un-
adjusted, and adjusted for the above socio-demographic
factors, using Poisson GEE models. Of note, as indicated in
the results, the data were not analyzed longitudinally given
that the number of incident reports of IPV (i.e. no report of
IPV at month-12 but IPV reported at month-24) was small.
Given that previous studies have linked depression to
IPV and to sexual risk behaviour, further analyses were per-
formed in order to examine the role of depressive symp-
toms on the relationship between IPV and sexual
behaviour, and findings are briefly described in the text.
These analyses investigated associations of: (i) depression
with sexual behaviours in unadjusted and socio-demo-
graphic adjusted GEE models, (ii) IPV measures with sexual
behaviours adjusted additionally for depression in GEE
models, and (iii) lifetime IPV victimization with sexual be-
haviours among men with depression and among men
without depression, via use of interaction terms in un-
adjusted GEE models.
For each measure and at each time-point, the propor-
tion of missing responses was < 5%. For sexual behav-
iours, psychosocial measures (sexualized drug use,
internalized homophobia, and IPV), and socio-economic
factors (university education and employment), missing
responses were considered to indicate that the event did
not occur, as there appeared to be a common response
pattern in which only those experiences that had
occurred were ticked on the questionnaire. A sensitivity
analysis was undertaken excluding missing values when
defining each variable. All analyses were performed in
STATA statistical software (version 13) [35] and
reported according to the STROBE guidelines [36].
Results
In total, 540 of the 544 participants enrolled in PROUD
completed a baseline questionnaire, 410 completed a
12-month questionnaire, and 333 completed a 24-month
questionnaire. The current analysis is based on 436 men
who completed either a 12- or 24-month questionnaire
(743 questionnaire responses in total). The vast majority
of participants who completed the 12-month question-
naire reported being gay (95.6%) and white ethnicity
(82.2%). The median age was 37 years (Interquartile
range [IQR]: 31–44 years). Forty percent of men were
born outside the UK and the majority reported univer-
sity degree level education (62.4%), being employed
(81.0%), and attending a study clinic in London (70.5%)
(Table 1). Socio-demographic characteristics of the par-
ticipants who completed the 24-month questionnaire
were very similar.
Prevalence of IPV
In Figs. 1 and 2, the prevalence of psychological, phys-
ical, and sexual IPV victimization and perpetration at
month-12 and 24 are presented. Prevalence is described
below for the 12-month data; results were similar at
month-24. Overall, 44.9% (184/410; 95% CI: 40.1, 49.7%)
of participants reported IPV victimization in their life-
time and 15.6% (64/410; 95% CI: 12.4, 19.5%) in the last
year. The most common form of victimization was being
frightened of a partner’s behaviour, reported by 39.4% (n
= 154) of men in their lifetime. Having experienced
physical violence from a partner was also common, be-
ing reported by 24.4% (n = 96) of men. Sixteen percent
(n = 63) of participants reported having been forced to
have sex (‘Have you ever been forced to have sex or made
to engage in some sexual activity when you did not want
to’) and 10% (n = 38) reported having been forced to
have sex without a condom (‘Have you ever been forced
to have sex without a condom when you did not want
to’) in their lifetime. In total, 19.5% (80/410; 95% CI:
15.9, 23.7%) of participants reported IPV perpetration in
their lifetime and 7.8% (32/410; 95% CI: 5.6, 10.8%) in
the last year. Having behaved in a manner that fright-
ened a partner and having been physically violent were
the most common forms of IPV perpetration, at 15.1%
(n = 59) and 12.1% (n = 48) respectively. With the
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Table 1 Adjusted associations with lifetime IPV victimization and IPV victimization in the last year, using pooled 12/24-month data
N = 743 observations (using pooled 12/24
data in GEE models; N = 436 men)
Lifetime IPV victimization IPV victimization
in the last year
% (n/N) Adjusteda PR [95% CI]
Overall p valuec
% (n/N) Adjusteda PR [95% CI]
Overall p valuec
Study time-point Month-12 44.9% (184/410) 1 15.6% (64/410) 1
Month-24 40.2% (134/333) 0.92 [0.76, 1.10] 14.7% (49/333) 0.98 [0.69, 1.40]
0.36 0.93
Randomized to study trial arm Immediate 42.0% (167/398) 1 15.8% (63/398) 1
Deferred 43.8% (151/345) 1.05 [0.82, 1.35] 14.5% (50/345) 0.89 [0.60, 1.32]
0.70 0.57
London study clinic site Yes 40.6% (210/517) 1 14.3% (74/517) 1
No 47.8% (108/226) 1.18 [0.89, 1.56] 17.3% (39/226) 1.31 [0.85, 2.02]
0.24 0.23
Age < 25 55.3% (21/38) 1.27 [0.75, 2.15] 23.7% (9/38) 1.61 [0.73, 3.59]
25–29 48.4% (44/91) 1.19 [0.80, 1.77] 19.8% (18/91) 1.32 [0.71, 2.44]
30–34 39.4% (63/160) 0.94 [0.65, 1.36] 13.1% (21/160) 0.83 [0.45, 1.51]
35–39 47.2% (68/144) 1.10 [0.76, 1.59] 16.0% (23/144) 1.02 [0.57, 1.84]
40–44 35.0% (44/125) 0.86 [0.58, 1.28] 11.2% (14/125) 0.74 [0.38, 1.44]
45+ 42.2% (78/185) 1 15.1% (28/185) 1
0.61 0.44
0.31 b 0.27 b
Born in the UK and ethnicity (BAME = Black, Asian,
and minority ethnic)
Yes, white 45.0% (183/407) 1 14.3% (58/407) 1
Yes, BAME 51.3% (20/39) 1.18 [0.70, 1.99] 20.5% (8/39) 1.40 [0.63, 3.10]
No, white 39.1% (79/202) 0.90 [0.66, 1.23] 12.9% (26/202) 0.97 [0.58, 1.62]
No, BAME 37.6% (35/93) 0.84 [0.54, 1.31] 22.6% (21/93) 1.83 [1.04, 3.20]
0.69 0.15
Self-reported sexual identity Gay 43.1% (303/703) 1 15.2% (107/703) 1
Bisexual/
straightd
29.4% (10/34) 0.62 [0.29, 1.30] 14.7% (5/34) 0.84 [0.32, 2.22]
0.21 0.73
University Education Yes 42.0% (193/460) 1 15.7% (72/460) 1
No/missing 44.2% (125/283) 1.01 [0.77, 1.32] 14.5% (41/283) 0.84 [0.55, 1.29]
0.96 0.43
Employed Yes 41.3% (251/608) 1 14.5% (88/608) 1
No/missing 49.6% (67/135) 1.17 [0.85, 1.62] 18.5% (25/135) 1.17 [0.70, 1.94]
0.33 0.55
Had sex after using recreational drugs
(past three months)
No/missing 38.1% (137/360) 1 10.8% (39/360) 1
Yes 47.3% (181/383) 1.36 [1.08, 1.71] 19.3% (74/383) 1.92 [1.28, 2.90]
0.010 0.002
Group sex (past three months) No/missing 42.1% (150/356) 1 11.0% (39/356) 1
Yes 43.4% (168/387) 1.10 [0.88, 1.38] 19.1% (74/387) 1.87 [1.25, 2.79]
0.38 0.002
Age < 13 years at anal sex debut No 43.7% (295/675) 1 15.3% (103/675) 1
Yes 53.7% (22/41) 1.15 [0.72, 1.84] 22.0% (9/41) 1.49 [0.74, 3.03]
0.57 0.27
Age≤ 15 years at anal sex debut No 42.3% (236/558) 1 14.7% (82/558) 1
Yes 51.3% (81/158) 1.18 [0.89, 1.56] 19.0% (30/158) 1.33 [0.85, 2.08]
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exception of one man at the 24-month follow-up, all indi-
viduals responded with ‘never’ to the two sexual IPV per-
petration questions (see Figs. 1 and 2). Overall, at
month-12, 16.8% of men (69/410; 95% CI: 13.5, 20.8%) re-
ported both lifetime IPV victimization and lifetime IPV
perpetration. Unidirectional IPV victimization was re-
ported by 28.1% of men (155/410; 95% CI: 23.9, 32.6%),
and unidirectional IPV perpetration by 2.7% (11/410; 95%
CI: 1.5, 4.8%). Due to small numbers, unidirectional IPV
perpetration was not investigated in further analyses.
In terms of changes in individual IPV status between
time-points among the 307 men who completed both
the 12- and 24-month questionnaire; of 134 men who
reported lifetime IPV victimization at month-12, 85
(63.4%) continued to report this measure of IPV at
month-24. Of 58 men who reported lifetime IPV perpet-
ration at month-12, 35 (60.3%) continued to report this
measure of IPV at month-24. Of the 173 men who did
not report lifetime IPV victimization at month-12, 39
(22.5%) reported it at month-24. Of the 249 men who
did not report lifetime IPV perpetration at month-12, 19
(7.6%) reported it at month-24. Of note, of 47 men who
reported IPV victimization in the last year at month-12,
14 (29.8%) reported it again at month-24. Of the 24 men
who reported IPV perpetration in the last year at
month-12, 6 (25.0%) reported it again at month-24.
At month-12, of the 70 participants who reported IPV
victimization or perpetration within the last year, 72.9%
(51/70) reported that joining PROUD had not influenced
IPV behaviours, 21.4% (15/70) reported it had influenced
them in a positive way, and no one reported it had influ-
enced them in a negative way (5.7% had a missing re-
sponse). At month-24, the equivalent data showed that
65.5% (36/55) reported that joining PROUD had not in-
fluenced IPV behaviours, 18.2% (10/55) reported it had
influenced them in a positive way, and 3.6% (2/55) in a
negative way (12.7% had a missing response). The two
men who reported a negative influence reported IPV at
month-24 but not month-12. Both reported being fright-
ened of the behaviour of a current/former partner in the
last year, and one of them reported being forced to have
sex in the last year with a current partner.
Association of socio-demographic and psychosocial
factors with IPV
Table 1 shows adjusted associations with lifetime IPV
victimization and IPV victimization in the last year. As-
sociations are adjusted for age, born in the UK, sexual
identity, university education, and London study clinic
site. Unadjusted PRs were very similar to the adjusted
PRs presented. Lifetime and past year measures of IPV
victimization were strongly associated with sexualized
drug use, a marker of internalized homophobia, and life-
time IPV perpetration, and for past year experiences of
IPV only, group sex. Of note, of the 224 men who re-
ported sexualized drug use at month-12, 67.9% had re-
ported the use of drugs most commonly associated with
chemsex (mephedrone, GHB/GBL, and/or metham-
phetamine) in the past three months at baseline. Mea-
sures of IPV victimization were not associated with
study time-point, trial arm, clinic site, age, country of
birth/ethnicity, sexual identity, university education, em-
ployment, age < 13 or age ≤ 15 years at anal sex debut, or
being out to all friends/work colleagues/close family.
Adjusted associations with lifetime IPV perpetration
and IPV perpetration in the last year are shown in Table 2.
Table 1 Adjusted associations with lifetime IPV victimization and IPV victimization in the last year, using pooled 12/24-month data
(Continued)
N = 743 observations (using pooled 12/24
data in GEE models; N = 436 men)
Lifetime IPV victimization IPV victimization
in the last year
% (n/N) Adjusteda PR [95% CI]
Overall p valuec
% (n/N) Adjusteda PR [95% CI]
Overall p valuec
0.26 0.21
Negative attitudes towards gay sexuality No/missing 38.3% (166/434) 1 10.8% (47/434) 1
Yes 49.2% (152/309) 1.31 [1.05, 1.64] 21.4% (66/309) 2.00 [1.36, 2.94]
0.016 < 0.001
‘Out’ to all/almost all friends, work mates,
and close family
Yes 44.6% (166/372) 1 14.0% (52/372) 1
No 42.3% (150/355) 1.08 [0.86, 1.36] 17.2% (61/355) 1.25 [0.85, 1.85]
0.52 0.25
Lifetime IPV perpetration No/missing 32.0% (193/603) 1 8.8% (53/603) 1
Yes 89.3% (125/140) 2.69 [2.11, 3.42] 42.9% (60/140) 4.72 [3.22, 6.93]
< 0.001 < 0.001
aAge (< 25, 25–29, 30–39, 40+), born in the UK, sexual identity (gay or bisexual/straight), university education, and London study clinic site
bTest for trend
cp value by Wald test using GEEs. p values< 0.1 are indicated in bold
dFive men identified as straight (1.2%)
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Table 2 Adjusted associations with lifetime IPV perpetration and IPV perpetration in the last year, using pooled 12/24-month data
N = 743 observations (using pooled 12/24
data in GEE models; N = 436 men)
Lifetime IPV perpetration IPV perpetration in the last year
% (n/N) Adjusteda PR [95% CI]
Overall p valuec
% (n/N) Adjusteda PR [95% CI]
Overall p valuec
Study time-point Month-12 19.5% (80/410) 1 7.8% (32/410) 1
Month-24 18.0% (60/333) 0.98 [0.76, 1.25] 6.9% (23/333) 0.99 [0.58, 1.68]
0.86 0.98
Randomized to study trial arm Immediate 19.9% (79/398) 1 7.8% (31/398) 1
Deferred 17.7% (61/345) 0.89 [0.60, 1.32] 7.0% (24/345) 0.81 [0.46, 1.41]
0.56 0.45
London study clinic site Yes 18.4% (95/517) 1 7.9% (41/517) 1
No 19.9% (45/226) 1.01 [0.65, 1.57] 6.2% (14/226) 0.71 [0.37, 1.35]
0.99 0.30
Age < 25 34.2% (13/38) 2.12 [1.04, 4.30] 18.4% (7/38) 5.53 [1.80, 17.0]
25–29 31.9% (29/91) 1.79 [1.00, 3.20] 19.8% (18/91) 5.89 [2.30, 15.10]
30–34 15.0% (24/160) 0.92 [0.50, 1.70] 5.6% (9/160) 1.73 [0.60, 4.97]
35–39 18.8% (27/144) 1.25 [0.69, 2.24] 7.6% (11/144) 2.26 [0.81, 6.28]
40–44 16.0% (20/125) 0.98 [0.53, 1.82] 3.2% (4/125) 0.98 [0.27, 3.57]
45+ 14.6% (27/185) 1 3.2% (6/185) 1
0.09 < 0.001
0.034b < 0.001b
Born in the UK and white ethnicity
(BAME = Black, Asian, and minority ethnic)
Yes, white 19.2% (78/407) 1 7.1% (29/407) 1
Yes, BAME 25.6% (10/39) 1.06 [0.48, 2.35] 12.8% (5/39) 1.10 [0.40, 3.05]
No, white 17.8% (36/202) 1.05 [0.65, 1.70] 6.4% (13/202) 0.97 [0.48, 1.95]
No, BAME 17.2% (16/93) 0.92 [0.47, 1.78] 8.6% (8/93) 1.13 [0.49, 2.61]
0.98 0.99
Self-reported sexual identity Gay 18.9% (133/703) 1 7.4% (52/703) 1
Bisexual/
straightd
17.7% (6/34) 0.79 [0.30, 2.08] 8.8% (3/34) 0.91 [0.27, 3.04]
0.63 0.88
University Education Yes 23.0% (65/283) 1 9.2% (26/283) 1
No/missing 16.3% (75/460) 1.31 [0.87, 1.96] 6.3% (29/460) 1.28 [0.73, 2.25]
0.19 0.39
Employed Yes 19.4% (118/608) 1 7.7% (47/608) 1
No/missing 16.3% (22/135) 0.68 [0.39, 1.20] 5.9% (8/135) 0.60 [2.67, 1.34]
0.18 0.21
Had sex after using recreational drugs
(past three months)
No/missing 12.5% (45/360) 1 4.2% (15/360) 1
Yes 24.8% (95/383) 1.75 [1.23, 2.50] 10.4% (40/
383)
2.16 [1.17, 3.96]
0.002 0.013
Group sex (past three months) No/missing 15.7% (56/356) 1 6.5% (23/356) 1
Yes 21.7% (84/387) 1.38 [1.00, 1.91] 8.3% (32/387) 1.42 [0.82, 2.46]
0.050 0.21
Age < 13 years at anal sex debut No 19.6% (132/675) 1 7.6% (51/675) 1
Yes 17.0% (7/41) 1.01 [0.48, 2.13] 7.3% (3/41) 1.06 [0.33, 3.44]
0.98 0.92
Age≤ 15 years at anal sex debut No 18.1% (101/558) 1 7.2% (40/558) 1
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Lifetime and past year measures of IPV perpetration were
strongly associated with younger age and sexualized drug
use. The prevalence of lifetime IPV perpetration was more
than eight times higher in men who reported IPV
victimization, and the prevalence of past year IPV perpet-
ration was almost 14 times higher in men who reported
IPV victimization, compared to men who did not. There
was some evidence that internalized homophobia was as-
sociated with lifetime IPV perpetration, and a strong asso-
ciation was found with past year experiences of IPV
perpetration. There was some evidence that group sex
was associated with lifetime IPV perpetration, but not IPV
perpetration in the last year.
Relationship between IPV and depressive symptoms
The prevalence of depressive symptoms was 14.4% at
month-12 (59/410) and month-24 (48/333). In the pooled
analysis, depressive symptom prevalence was approxi-
mately three times higher in men who reported IPV
victimization (lifetime or last year). There were similar,
and stronger, associations for IPV perpetration measures
(lifetime or last year) (Table 3). Compared to men who re-
ported no experiences of IPV, the prevalence of depression
was almost twice as high in men who reported unidirec-
tional victimization and more than three times higher in
men who reported both victimization and perpetration.
Relationship between IPV and sexual behaviour
Measures of lifetime and past year IPV victimization and
perpetration were not associated with sexual risk
behaviours in GEE models (see Figs. 3 and 4). Un-
adjusted PRs were very similar to the adjusted PRs pre-
sented. There was some suggestion of a link between
IPV victimization and receptive CAS with an
HIV-positive partner not known to be on antiretroviral
treatment, although this relationship did not reach stat-
istical significance. Experiences of unidirectional IPV
victimization and both victimization and perpetration
were not associated with CAS measures or partner num-
bers in unadjusted or adjusted analyses.
Impact of depression on relationship between IPV and
sexual behaviour
Depressive symptoms were not associated with sexual risk
behaviours in unadjusted or adjusted analysis (see Add-
itional file 2). Associations between IPV measures and sex-
ual behaviours remained the same after adjusting
additionally for depressive symptoms. The relationship be-
tween lifetime IPV victimization and sexual behaviours was
not different among men who reported depressive symp-
toms and men who did not; the interaction p values were
not significant for any of the sexual behaviours (p ≥ 0.3).
Handling missing data
A sensitivity analysis was undertaken excluding missing
values when defining each variable. The findings were
very similar to the main analysis.
Discussion
This study found that measures of IPV were associated
with younger age (perpetration only), sexualized drug
Table 2 Adjusted associations with lifetime IPV perpetration and IPV perpetration in the last year, using pooled 12/24-month data
(Continued)
N = 743 observations (using pooled 12/24
data in GEE models; N = 436 men)
Lifetime IPV perpetration IPV perpetration in the last year
% (n/N) Adjusteda PR [95% CI]
Overall p valuec
% (n/N) Adjusteda PR [95% CI]
Overall p valuec
Yes 24.1% (38/158) 1.32 [0.88, 1.99] 8.9% (14/158) 0.93 [0.48, 1.77]
0.18 0.82
Negative views about gay sexuality No/missing 16.8% (73/434) 1 5.1% (22/434) 1
Yes 21.7% (67/309) 1.33 [0.97, 1.83] 10.7% (33/
309)
2.10 [1.21, 3.65]
0.075 0.008
‘Out’ to all/almost all friends, work mates,
and close family
Yes 22.6% (84/372) 1 8.1% (30/372) 1
No 15.8% (56/355) 0.79 [0.56, 1.12] 7.0% (25/355) 0.93 [0.53, 1.62]
0.19 0.79
Any IPV victimization No/missing 3.5% (15/425) 1 1.2% (5/425) 1
Yes 39.3% (125/318) 8.47 [5.09, 14.09] 15.7% (50/
318)
13.54 [5.33, 34.38]
< 0.001 < 0.001
aAge (included as four categories: < 25, 25–29, 30–39, 40+), born in the UK, sexual identity (gay or bisexual/straight), university education, and London clinic site
bTest for trend
cp value by Wald test using GEEs. p values< 0.1 are indicated in bold
dFive men identified as straight (1.2%)
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use, internalized homophobia, group sex, and were
strongly associated with depressive symptoms. IPV was
not consistently associated with CAS measures among
this study population.
The prevalence of IPV in the PROUD trial of GBMSM
was very high: 44.9% (95% CI: 40.1, 49.7%) for lifetime IPV
victimization and 15.6% (95% CI: 12.4, 19.5%) in the last
year, and 19.5% (95% CI: 15.9, 23.7%) for lifetime IPV per-
petration, and 7.8% (95% CI: 5.6, 10.8%) in the last year, at
the 12-month questionnaire. There was some inconsist-
ency of reporting of lifetime IPV between month-12 and
24 in PROUD. However, among those who reported IPV
at month-12 but not 24, a common pattern of response
was for men to report being frightened of the behaviour of
a partner/having behaved in a manner that frightened a
partner at month-12 and to respond ‘Never’ at month-24.
Possibly, individuals may forget a single instance of IPV of
this nature, view such an occurrence with less significance
after a period of time, or ascribe a different meaning to it
in the light of changes in the relationship or other
circumstances.
The prevalence of IPV in PROUD is high when com-
pared to the Crime Survey for England and Wales
(2016) and the UK population-based Adult Psychiatric
Morbidity Survey (2007, physical and/or emotional IPV
only) whereby lifetime prevalence of IPV victimization
was 10.1% (95% CI: 9.5, 10.7%) and 18.7% (95% CI: 17.1,
20.4%) for men respectively in the two studies, and
23.0% (95% CI: 22.2, 23.8%) and 27.8% (95% CI: 26.2,
29.4%) for women [9, 10]. However, both of these studies
used a different assessment of IPV and did not present
data separately for GBMSM. Estimates from PROUD are
more in line with, although still higher than, those from
a London GUM clinic cross-sectional study of gay- and
bisexual-identified men (2010–2011, N = 519), which
used the same measure of IPV (excluding ‘forced to have
sex without a condom’): 33.9% (95% CI: 29.4, 37.9%) for
lifetime IPV victimization and 16.3% (95% CI: 13.0,
19.8%) for lifetime IPV perpetration [7]. However, a
qualitative study with 19 of these men, suggested that
the survey results underestimated the prevalence of IPV
[37]. PROUD estimates of lifetime IPV and IPV in the
last year were also somewhat similar compared to those
reported in two UK online samples of GBMSM that
used different assessments of IPV. In one online study of
398 GBMSM [6], past year estimates of IPV were 8.5%
(95% CI: 6.0, 11.7%) for physical IPV victimization, 3.3%
(95% CI: 1.8, 5.5%) for physical IPV perpetration, 4.5%
(95% CI: 2.7, 7.1%) for sexual IPV victimization, and
0.8% (95% CI: 0.2, 2.2%) for sexual IPV perpetration. In
the other online study of 258 GBMSM [8], the preva-
lence of lifetime IPV victimization was 36.4% (95% CI:
Table 3 Unadjusted and adjusted associations of IPV measures with depressive symptoms
N = 743 observations (using pooled 12/24
data in GEE models; N = 436 men)
Clinically significant depressive symptoms (PHQ-9≥ 10)
14.4% (107/743)
% (n/N) Unadjusted PR [95% CI]
Overall p valueb
Adjusteda PR [95% CI]
Overall p valueb
Lifetime IPV victimization No/missing 8.9% (38/425) 1 1
Yes 21.7% (69/318) 2.45 [1.63, 3.67] 2.57 [1.71, 3.86]
< 0.001 < 0.001
IPV victimization in last year No/missing 11.1% (70/630) 1 1
Yes 32.7% (37/113) 2.82 [1.88, 4.22] 2.93 [1.96, 4.40]
< 0.001 < 0.001
Lifetime IPV perpetration No/missing 10.8% (65/603) 1 1
Yes 30.0% (42/140) 2.83 [1.89, 4.22] 2.87 [1.91, 4.32]
< 0.001 < 0.001
IPV perpetration in last year No/missing 12.1% (83/688) 1 1
Yes 43.6% (24/55) 3.40 [2.13, 5.41] 3.47 [2.13, 5.64]
< 0.001 < 0.001
Combined lifetime IPV victimization/
perpetrationc
Vict. & perp. 31.2% (39/125) 3.69 [2.33, 5.86] 3.87 [2.43, 6.16]
Undirectional vict. 15.5% (30/193) 1.74 [1.07, 2.82] 1.83 [1.13, 2.98]
Neither /missing 8.9% (38/425) 1 1
< 0.001 < 0.001
aAge (included as four categories: < 25, 25–29, 30–39, 40+), born in the UK, sexual identity (gay or bisexual/straight), university education, and London clinic site
bp value by Wald test using GEEs. p values< 0.1 are indicated in bold
cMen who reported unidirectional IPV perpetration were excluded since the number of men reporting this measure (n = 11 at month-12 and n = 4 at month-24)
was too small to allow for meaningful analysis, and these men did not fit into the ‘neither/missing’ category
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30.6, 42.6%). Men may have been more likely to disclose
IPV within the PROUD clinical trial setting, given more
frequent contact with healthcare professionals and there-
fore opportunities for support and referral. Differences
observed may also be attributed to the unique behav-
ioural profile of the PROUD sample: there was a very
high proportion who reported STIs and recreational
drug use at baseline, very high levels of CAS at baseline
and follow-up, and an exceptionally high incidence of
HIV in the control group [15, 16], factors which may be
associated with IPV. Therefore, IPV prevalence in
PROUD may differ from other samples of GBMSM, and
is not generalizable to the general GBMSM population
in England.
In the current study, a trend was found with younger
age and increasing prevalence of IPV perpetration, as
has been found in other samples of GBMSM [38, 39].
Although no associations were found of sexual identity
or ethnicity with lifetime and past year measures of IPV,
the vast majority of the PROUD sample were gay identi-
fied and of white ethnicity. Furthermore, findings from a
recent qualitative study suggest that dyadic inequalities
including education and income differentials may serve
as a means by which to establish power dynamics in
same-sex male couples, and increase the risk of experi-
encing control and abuse from a partner [40]. The
PROUD study sample likely lacked the statistical power
to investigate these associations.
Having been a victim of IPV was very strongly associated
with IPV perpetration in PROUD. It has been posited,
across psychoanalytic theories, that exposure to/experi-
ences of violence, abuse, and neglect, precede the perpetra-
tion of violence in future relationships [41–56]. The
association between IPV victimization and IPV perpetra-
tion may be bidirectional. The very strong relationship
observed in this study, may also reflect the phenomena of
Fig. 3 Adjusted associations of lifetime and past year measures of IPV victimization with sexual behaviours in the past three months among 436 men who
participated in PROUD. a CAS with at least two receptive or at least two insertive CAS partners. b CAS with at least five receptive or at least five insertive
CAS partners. c Not known to be on HIV treatment. d The model was fitted to include age in four categories (< 25; 25–29; 30–39; 40+), dichotomous UK
born and self-reported sexual identity
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reciprocal IPV. In Johnson’s categorizations of IPV in
opposite-sex partnerships, abuse may take one of four
forms: (i) intimate terrorism, whereby one partner carries
out abuse via a range of control tactics that are likely to es-
calate over time in a cyclical pattern of abuse, remorse,
pursuit, and tension build-up, (ii) mutual violent control,
whereby both partners are abusive and controlling, (iii)
violent resistance, whereby one partner is violent and the
other responds in violent self-defense, or (iv) situational
couple violence, whereby one or both partners are abusive
but the abuse is not attached to a pattern of escalating con-
trol [57]. In the current study, 16.8% of men reported life-
time experiences of IPV both as a victim and a perpetrator,
although it was not possible to distinguish abuse carried
out with the same or different partner. Further research is
needed to examine whether the dynamics of IPV among
same-sex male couples fit within Johnson’s four categories,
and what processes are involved in the manifestation of
these dynamics.
Evidence is accumulating which suggests that among
UK (N = 398 [6]), U.S. (N = 1575 [4], N = 750 [5]), and
Canadian (N = 186 [58]) samples of GBMSM, markers of
internalized homophobia are strongly associated with
measures IPV perpetration, including physical, [6, 58],
emotional/psychological [58] and sexual [4, 5], in un-
adjusted analysis [4, 58], and after adjusting for
socio-demographic and lifestyles factors [5, 6]. Associa-
tions have also been found with measures of IPV
victimization in the U.S., including physical and sexual
[5, 6]. In the current study, a marker of internalized
homophobia was strongly associated with experiences of
IPV victimization and IPV perpetration.
Fig. 4 Adjusted associations of lifetime and past year measures of IPV perpetration with sexual behaviours in the past three months among 436 men who
participated in PROUD. a CAS with at least two receptive or at least two insertive CAS partners. b CAS with at least five receptive or at least five insertive
CAS partners. c Not known to be on HIV treatment. d The model was fitted to include age in four categories (< 25; 25–29; 30–39; 40+), dichotomous UK
born and self-reported sexual identity
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For sexual minority individuals, the internalization of
anti-gay attitudes leads to feelings of worthlessness and
negativity about the self, and may be linked to pervasive
expectations of rejection, and non-disclosure of one’s
sexual orientation. The link between internalized homo-
phobia and IPV may be explained by exosystem factor
theory and psychoanalytic theories. In exosystem factor
theory, stress that is associated with exosystem level fac-
tors, the cultural or sub-cultural context in which devel-
opment occurs, and is perceived to exceed one’s
financial/emotional resources, is thought to be an im-
portant trigger for the perpetration of violence. This
may occur in particular, against the backdrop of expos-
ure to abuse/violence in childhood or early adolescence
and lack of social support [59, 60]. Sexual identity is an
exosystem level factor if an individual affiliates with a
sexual minority population in a community. The stress
associated with social pressure to conform to heteronor-
mative behaviours may play some role in IPV perpetra-
tion among gay and plurisexual identified men. Enacting
hegemonic masculinity via violent domination of one’s
partner, may be used as a way of reconstructing a con-
tested masculinity [61]. In psychoanalytic theories, abuse
from significant individuals during formative years can
manifest in persistent feelings of unworthiness, and an
inability to regulate emotional responses and recognize/
avoid abuse in adult intimate partnerships. Some indi-
viduals develop complex psychological defences neces-
sary for survival, which become highly integrated into
one’s personality structure [43, 46]. Although not
possible in the current study, an understanding of the
degree of exposure to abuse in childhood/adolescence,
and emotional ties formed with primary caregivers, as
well as levels of social support, may provide insight into
why some men who experience internalized homophobia
have violent partnerships while others do not.
In a UK study of GBMSM, IPV victimization in the
last year was associated with past year use of ecstasy,
LSD, cocaine, crack, heroin, or injected amphetamines
(OR 1.7 95% CI: 1.16, 2.47, p = 0.006), after adjusting
for socio-demographics [7]. Findings from PROUD
suggest that sexualized drug use, which to a large ex-
tent may encompass the practice of chemsex, may be
important in the context of IPV among GBMSM. Sex-
ualized drug use (chemsex) may occur in group sex-
ual settings. In this study, men who reported group
sex were more likely to report IPV victimization in
the last year, and there was some suggestion of a link
with lifetime IPV perpetration. Group sex environ-
ments may leave some individuals vulnerable to mis-
treatment particularly if drugs are used, given their
impact on inhibition and self-regulation [29, 62]. The
relationship between recreational drug use and IPV
may be bidirectional such that drugs are used as a
form of self-medication and/or in order to induce a
state of cognitive release [63].
Strong associations were found between IPV and de-
pressive symptoms in the PROUD trial. This is in line
with evidence from a recent meta-analysis of GBMSM
[3], and suggests that experiences of IPV may have a
lasting adverse impact on mental health. In PROUD, the
association with depression was particularly strong for
IPV perpetration, including men who both experienced
and perpetrated abuse. Similarly, in the only UK study to
have examined the link between IPV and depression
among GBMSM, the prevalence of depression
(HADS≥8) was significantly elevated among men report-
ing IPV perpetration in the past year versus those who
hadn’t (20.7% vs. 11.5%), but not among men reporting
victimization (past year or lifetime) [7]. In that study,
after adjusting for socio-demographic factors, the associ-
ation between IPV perpetration and depression was at-
tenuated to borderline significance (OR 3.7 95% CI: 1.0,
14.6; p = 0.060). However, income was adjusted for,
which may be highly correlated with both IPV and de-
pression. When comparing these survey study findings to
those provided during an interview, there was evidence to
suggest that some men who abuse a partner do not report
it on a survey questionnaire [37]. It is possible that for those
men who do, the experience of IPV may have had a greater
psychological impact. IPV perpetration is highly correlated
with abusive experiences in childhood [43, 46, 59, 60, 64–
66]. It is possible that a greater degree of exposure to vio-
lence during formative years may also explain a higher
prevalence of depression among individuals who have car-
ried out IPV. The relationship between depression and IPV
may be bidirectional such that depressive symptoms
heighten vulnerability to dysfunctional relationship dynam-
ics, as adaptive coping mechanisms are distorted [67, 68].
Physical acts of violence directed towards an intimate
partner do not often occur in isolation, frequently there
is overlap with other forms of violence, including sexual
abuse [69]. IPV may lead to a distortion of one’s percep-
tion of self-worth and ability to recognize dysfunctional
relationship dynamics [56]. It is therefore plausible, that
experiences of IPV with a previous partner may also lead
to unwanted sex and CAS with other partners. In a re-
cent meta-analysis [3], exposure to any kind of IPV was
associated with CAS (pooled OR: 1.72 95% CI: 1.44,
2.05) and HIV seropositivity (pooled OR: 1.46 95% CI:
1.26, 1.69). In the current study, there was some sugges-
tion of an association between lifetime IPV victimization
and receptive CAS with an HIV-positive partner not
known to be on antiretroviral treatment. However, mea-
sures of IPV were not found to be associated with any
other measures of CAS or partner numbers in the
PROUD trial. Similarly, no associations were found be-
tween depressive symptoms and sexual risk behaviour,
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despite the evidence for a relationship in other high-in-
come country studies of GBMSM [70, 71]. There was no
evidence from PROUD to suggest a synergistic effect of
IPV and depression on sexual risk behaviour. The
unique nature of the PROUD study population, GBMSM
who reported very high levels of CAS, may explain why
associations with CAS measures were not seen for de-
pression or IPV. Perhaps IPV and depression do not ex-
plain why some men who engage in CAS have a higher
number of CAS partners. It may be that other factors,
with greater disinhibiting effects, such as higher levels of
recreational drug use and/or personality traits associated
with sexual compulsivity/sensation seeking, play a greater
role in this context.
The role of GUM services in addressing IPV
The UK National Institute for Health and Care Excellence
recommends that trained staff in sexual health services ask
about IPV as part of good clinical practice, even where
there are no indicators of violence and abuse [72]. However,
a recent UK survey (2010–2011) found that only 34.7% of
522 gay and bisexual GUM clinic attendees felt that ‘health
professionals should ask all patients whether they have been
hurt/frightened by a partner’, whereas 62.6% felt only some
patients should be asked based on symptoms [37]. Further
qualitative exploration revealed that men perceived the
busy clinic environment as not conducive to asking all pa-
tients about IPV in a manner that would encourage disclos-
ure. Conversely, some men felt that selective enquiry could
be stigmatizing. At the very least sexual health services
should display information on IPV, as well as train staff to
recognize the common indicators, enquire sensitively
about violence, and refer patients to further support
within and outside of the health care setting. In the UK
context this includes referral to domestic and sexual vio-
lence advisors (IDSVA) and local IPV services. General
IPV support services for men include the ManKind Initia-
tive and the Everyman Project, which offers counseling in
London, as well as services specifically tailored to sexual
and gender minorities, such as the Respect Phoneline and
Galop LGBT Domestic Abuse Helpline, offering informa-
tion and support. The IRIS ADViSE model, which encom-
passes training to enhance recognition, enquiry, and
referral, has been shown to increase the IPV enquiry and
identification rate among female GUM clinic attendees in
a UK pilot study [73], and in a cluster randomized trial of
women attending general practitioners in the UK, the
identification of IPV and referral to specialist services [74].
In a recent RCT of Project WINGS, which aimed to pro-
vide effective IPV victimization screening, brief interven-
tion, and referral to treatment services (SBIRT) for
substance using women in New York, identification of
IPV and receipt of IPV services was found to increase after
3-months of follow-up [75].
Limitations
Information on the number and type of recreational drugs
used in the past three months and higher risk alcohol con-
sumption was only collected at the baseline questionnaire.
Not being able to investigate other factors, which may be
important in the context of IPV such as social support
and financial security, was also a limiting factor. It was not
possible to investigate data on dysfunctional relationships
formed with primary caregivers in childhood/early adoles-
cence. Not all PROUD participants were included in the
IPV analysis due to missing questionnaires at months 12
and 24. Participants lost to follow-up may differ in terms
of psychosocial factors. However, depression at baseline
was not associated with loss-to-follow-up (overall or in
each trial arm separately), and there was no difference be-
tween men with depressive symptoms and men without
symptoms at the 12-month questionnaire in terms of
completing the 24-month questionnaire (27.1% vs. 24.8%
lost-to-follow-up respectively; p-value = 0.702). There was
also no difference between men reporting experiences of
lifetime IPV victimization and men who did not at the
12-month questionnaire in terms of completing the
24-month questionnaire (27.2% vs. 23.5% lost-to-follow-up
respectively; p-value = 0.387). Even after including repeated
observations in GEE models, given the relatively small sam-
ple size of the PROUD trial, the analysis may have lacked
power to accurately detect the presence of some associa-
tions. GEEs were used for data-analysis in this paper, which
treat the data as if it were cross-sectional, prohibiting infer-
ences about causality. There is a need to conduct an
adequately powered longitudinal study designed to address
IPV among sexual minorities.
Conclusions
In the PROUD trial of GBMSM at high-risk of HIV acqui-
sition and seeking/taking PrEP, a very high lifetime preva-
lence of IPV was found. When addressing IPV, there is a
need to also acknowledge and bring to the fore, the preva-
lence of violence in same-sex male couples. Training on
IPV among same-sex couples should be enhanced in
GUM settings with ongoing support and supervision for
staff. Participation in the PROUD trial of PrEP efficacy did
not appear to negatively influence experiences of IPV
among GBMSM, and IPV prevalence was similar in both
arms of the trial. IPV was strongly associated with sexual-
ized drug use, internalized homophobia, and current
symptoms of depression, but not with CAS measures. The
impact of homophobia not only on one’s mental health
but also on dynamics within intimate partnerships needs
to be highlighted. Research is needed to better understand
the effect sexual minority stress may have on IPV, includ-
ing the magnitude of the effect and the direction and
mechanisms of association.
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